{"id":53817,"date":"2026-01-12T22:51:49","date_gmt":"2026-01-12T14:51:49","guid":{"rendered":"https:\/\/flcube.com\/?p=53817"},"modified":"2026-01-12T22:51:50","modified_gmt":"2026-01-12T14:51:50","slug":"alphamab-oncology-submits-envafolimab-for-first-line-biliary-tract-cancer-btc-as-worlds-first-subcutaneous-pd-l1","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53817","title":{"rendered":"Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1"},"content":{"rendered":"\n<p><strong>Alphamab Oncology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9966:HKG\">HKG:\u202f9966<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its marketing application for <strong>envafolimab<\/strong>, the <strong>world\u2019s first commercially available subcutaneous PD\u2011L1 inhibitor<\/strong>, in combination with <strong>GEMOX<\/strong> (gemcitabine and oxaliplatin) for the <strong>first\u2011line treatment of unresectable or metastatic biliary tract cancer (BTC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Supplemental New Drug Application (sNDA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Envafolimab (subcutaneous PD\u2011L1 inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First\u2011line BTC in combination with GEMOX<\/td><\/tr><tr><td><strong>Filing Acceptance Date<\/strong><\/td><td>10\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Review Timeline<\/strong><\/td><td>Standard (10\u2011month target)<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>MSI\u2011H\/dMMR advanced solid tumors (Nov\u202f2021)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-commercial-partnership\">Drug Profile &amp; Commercial Partnership<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Administration:<\/strong> Subcutaneous injection with <strong>~30\u2011second administration time<\/strong>, eliminating infusion\u2011center visits and reducing healthcare resource burden<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Programmed death\u2011ligand 1 (PD\u2011L1) inhibitor with demonstrated comparable efficacy to intravenous PD\u20111\/PD\u2011L1 agents<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Originated by Alphamab Oncology; global rights retained with regional licensing<\/li>\n\n\n\n<li><strong>Development Partner:<\/strong> Co\u2011development agreement with <strong>3D Medicines<\/strong> (January\u202f2019)<\/li>\n\n\n\n<li><strong>Commercial Rights:<\/strong> <strong>Simcere Pharmaceutical Group<\/strong> (2096.HK) holds exclusive promotion rights in mainland China (since March\u202f2020)<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> Only subcutaneous PD\u2011L1 inhibitor approved in China; positioned to capture market share through convenience and compliance advantages<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-revenue-forecast\">Market Opportunity &amp; Revenue Forecast<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>China BTC Incidence<\/strong><\/td><td>120,000<\/td><td>125,000<\/td><td>130,000<\/td><\/tr><tr><td><strong>Metastatic\/Unresectable Cases<\/strong><\/td><td>75,000<\/td><td>78,000<\/td><td>81,000<\/td><\/tr><tr><td><strong>Eligible for Envafolimab + GEMOX<\/strong><\/td><td>60,000<\/td><td>62,000<\/td><td>64,000<\/td><\/tr><tr><td><strong>Market Penetration<\/strong><\/td><td>0\u202f%<\/td><td>12\u202f%<\/td><td>22\u202f%<\/td><\/tr><tr><td><strong>Annual Treatment Cost (\u00a5)<\/strong><\/td><td>\u2013<\/td><td>\u00a598,000<\/td><td>\u00a594,000<\/td><\/tr><tr><td><strong>China Revenue Forecast<\/strong><\/td><td>\u2013<\/td><td>\u00a5728\u202fmillion<\/td><td>\u00a51.32\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> Current first\u2011line standard (GEMOX + IV immunotherapy) requires 2\u2011hour infusion; subcutaneous option targets <strong>30\u202f% of eligible patients by 2028<\/strong> seeking treatment convenience<\/li>\n\n\n\n<li><strong>Simcere\u2019s Commercial Reach:<\/strong> 1,200\u2011person oncology sales force covering 1,800 tertiary hospitals; 15\u2011month launch ramp projected post\u2011approval<\/li>\n\n\n\n<li><strong>Health Economics:<\/strong> Subcutaneous administration reduces per\u2011patient treatment time by 90\u202f%, saving ~\u00a512,000 annually in direct and indirect healthcare costs<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Agent<\/th><th>Company<\/th><th>Route<\/th><th>China BTC Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Envafolimab<\/strong><\/td><td>Alphamab\/Simcere<\/td><td>Subcutaneous<\/td><td>sNDA under review<\/td><\/tr><tr><td><strong>Toripalimab<\/strong><\/td><td>Junshi Biosciences<\/td><td>IV<\/td><td>Approved (first\u2011line BTC, 2023)<\/td><\/tr><tr><td><strong>Tyvyt (sintilimab)<\/strong><\/td><td>Innovent\/Eli Lilly<\/td><td>IV<\/td><td>Approved (first\u2011line BTC, 2022)<\/td><\/tr><tr><td><strong>Tecentriq (atezolizumab)<\/strong><\/td><td>Roche<\/td><td>IV<\/td><td>Approved (first\u2011line BTC, 2022)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Moat:<\/strong> Envafolimab\u2019s <strong>30\u2011second subcutaneous injection<\/strong> vs. 30\u201160\u202fminute IV infusions; potential for <strong>home\u2011based administration<\/strong> under physician supervision<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Expected 15\u201120\u202f% premium over IV PD\u20111\/PD\u2011L1 agents; NRDL inclusion anticipated <strong>2028<\/strong> following real\u2011world evidence generation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Synergy:<\/strong> Alphamab is evaluating envafolimab in <strong>adjuvant BTC<\/strong> (post\u2011surgery) and in combination with its <strong>CLDN18.2 ADC<\/strong>, potentially expanding addressable market by 40\u202f%<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Suzhou facility certified for 500,000 doses annually; scalable to 1.2\u202fmillion doses by 2027<\/li>\n\n\n\n<li><strong>Export Potential:<\/strong> Subcutaneous formulation under review by <strong>Korea MFDS<\/strong> and <strong>Singapore HSA<\/strong>; EU partnership discussions initiated<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory review timelines, commercial forecasts, and market penetration for envafolimab in biliary tract cancer. Actual results may differ due to NMPA approval conditions, competitive responses, and NRDL pricing negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026010901370_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026010901370_c.\"><\/object><a id=\"wp-block-file--media-de2ce287-2f10-4bb8-9373-e20772e9539f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026010901370_c.pdf\">2026010901370_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026010901370_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-de2ce287-2f10-4bb8-9373-e20772e9539f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alphamab Oncology (HKG:\u202f9966) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its marketing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[187,16,854,38,18],"class_list":["post-53817","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-alphamab-oncology","tag-cancer","tag-hkg-9966","tag-market-approval-filings","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alphamab Oncology (HKG:\u202f9966) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its marketing application for envafolimab, the world\u2019s first commercially available subcutaneous PD\u2011L1 inhibitor, in combination with GEMOX (gemcitabine and oxaliplatin) for the first\u2011line treatment of unresectable or metastatic biliary tract cancer (BTC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53817\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1\" \/>\n<meta property=\"og:description\" content=\"Alphamab Oncology (HKG:\u202f9966) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its marketing application for envafolimab, the world\u2019s first commercially available subcutaneous PD\u2011L1 inhibitor, in combination with GEMOX (gemcitabine and oxaliplatin) for the first\u2011line treatment of unresectable or metastatic biliary tract cancer (BTC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53817\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T14:51:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T14:51:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53817#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53817\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1\",\"datePublished\":\"2026-01-12T14:51:49+00:00\",\"dateModified\":\"2026-01-12T14:51:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53817\"},\"wordCount\":469,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alphamab Oncology\",\"Cancer\",\"HKG: 9966\",\"Market approval filings\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53817#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53817\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53817\",\"name\":\"Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T14:51:49+00:00\",\"dateModified\":\"2026-01-12T14:51:50+00:00\",\"description\":\"Alphamab Oncology (HKG:\u202f9966) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its marketing application for envafolimab, the world\u2019s first commercially available subcutaneous PD\u2011L1 inhibitor, in combination with GEMOX (gemcitabine and oxaliplatin) for the first\u2011line treatment of unresectable or metastatic biliary tract cancer (BTC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53817#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53817\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53817#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1 - Insight, China&#039;s Pharmaceutical Industry","description":"Alphamab Oncology (HKG:\u202f9966) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its marketing application for envafolimab, the world\u2019s first commercially available subcutaneous PD\u2011L1 inhibitor, in combination with GEMOX (gemcitabine and oxaliplatin) for the first\u2011line treatment of unresectable or metastatic biliary tract cancer (BTC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53817","og_locale":"en_US","og_type":"article","og_title":"Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1","og_description":"Alphamab Oncology (HKG:\u202f9966) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its marketing application for envafolimab, the world\u2019s first commercially available subcutaneous PD\u2011L1 inhibitor, in combination with GEMOX (gemcitabine and oxaliplatin) for the first\u2011line treatment of unresectable or metastatic biliary tract cancer (BTC).","og_url":"https:\/\/flcube.com\/?p=53817","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T14:51:49+00:00","article_modified_time":"2026-01-12T14:51:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53817#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53817"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1","datePublished":"2026-01-12T14:51:49+00:00","dateModified":"2026-01-12T14:51:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53817"},"wordCount":469,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alphamab Oncology","Cancer","HKG: 9966","Market approval filings","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53817#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53817","url":"https:\/\/flcube.com\/?p=53817","name":"Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T14:51:49+00:00","dateModified":"2026-01-12T14:51:50+00:00","description":"Alphamab Oncology (HKG:\u202f9966) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its marketing application for envafolimab, the world\u2019s first commercially available subcutaneous PD\u2011L1 inhibitor, in combination with GEMOX (gemcitabine and oxaliplatin) for the first\u2011line treatment of unresectable or metastatic biliary tract cancer (BTC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53817#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53817"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53817#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab Oncology Submits Envafolimab for First\u2011Line Biliary Tract Cancer (BTC) as World\u2019s First Subcutaneous PD\u2011L1"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53817"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53817\/revisions"}],"predecessor-version":[{"id":53819,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53817\/revisions\/53819"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}